109 results about "RSV Infections" patented technology

The invention belongs to the technical field of medicines, and discloses a common goldenrop decoction active ingredient composition and application thereof in prevention and treatment of human respiratory syncytial virus. The invention relates to application of an active ingredient composition (isoliquiritigenin, baicalein, 6-shogaol, schisandrin B, ferulic acid and methyl salicylate) of Xiaochaihu decoction and / or a derivative of the active ingredient or a pharmaceutically acceptable salt thereof in preparation of medicines for preventing, relieving and / or treating RSV (Respiratory Syndrome Virus) infectious diseases. According to the invention, by establishing a mouse RSV infection model, the effect and the action mechanism of the composition in preventing and treating RSV infection are evaluated. Results show that each dose group can inhibit replication of RSV in mouse lung tissues, relieve pulmonary edema, improve pathological changes of the lung, inhibit expression of inflammatory factors and improve humoral immunity, and the effect is equivalent to that of ribavirin. The radix bupleuri granules have better effects on relieving pulmonary edema and inhibiting virus proliferation compared with small radix bupleuri granules. The composition of the effective components of the common goldenrop can provide a new drug treatment scheme for clinical RSV infectious diseases.

The present invention provides mutant RSV F molecules that can be, or are, stabilized in the pre-fusion conformation (preF) by the introduction of one or more dityrosine (DT) crosslinks. The present invention also provides methods of making such mutant RSV F molecules, vaccine compositions comprising such mutant RSV F molecules, and methods of use of such mutant RSV F molecules, for example in vaccination methods to protect subjects against RSV infection.

Highly potent respiratory syncytial virus (RSV) neutralizing monoclonal antibodies that specifically bind RSV fusion protein (F) or RSV attachment glycoprotein (G) are described. The monoclonal antibodies were synthesized by sequencing RSV G- and RSV F-specific B cells from a human participant of an RSV challenge study. The RSV-specific monoclonal antibodies described herein exhibit potent neutralization of RSV (IC50 as low as 0.4 ng / ml) that is superior to previously disclosed RSV neutralizing antibodies. The RSV-specific monoclonal antibodies can be used, for example, to treat, inhibit and detect RSV infection.

The invention belongs to the technical field of medicines, and discloses application of an adeno-associated virus vector in preparation of medicines for preventing and treating RSV infection and / or diseases caused by RSV. According to the invention, a recombinant adeno-associated virus vector is adopted for the first time to construct a medicine for preventing and treating RSV infection or diseases caused by RSV infection, and based on this, the invention provides a nucleic acid molecule which comprises: (a1) a first region which comprises a first adeno-associated virus inverted terminal repeat sequence, and (a2) a second region which comprises a second adeno-associated virus inverted terminal repeat sequence; and (a2) a second region comprising a gene encoding a respiratory syncytial virus antigen; the recombinant adeno-associated virus containing the nucleic acid molecule can generate better humoral immune effect and cellular immune effect, has a certain serum neutralization effect on strains of A and B subtypes of RSV, and particularly, when the antigen is a fusion protein of the respiratory syncytial virus or a fusion protein mutant of the respiratory syncytial virus, the recombinant adeno-associated virus has a certain serum neutralization effect on the strains of A and B subtypes of the RSV. The recombinant adenovirus vector containing the nucleic acid molecule can successfully realize the expression of the F protein before RSV fusion.

The invention discloses a nano antibody of pre-F protein of a targeted respiratory syncytial virus and application of the nano antibody. The nano antibody comprises a heavy chain variable region, and the heavy chain variable region comprises heavy chain complementary determining regions CDR1, CDR2 and CDR3. The nano antibody disclosed by the invention can be specifically combined with RSV, and has a good application prospect in the aspect of RSV infection related diseases.

The present disclosure relates to the field of RNAs for the prevention or treatment of various infectious agents. In particular, the present disclosure relates to methods and agents for vaccination against coronavirus infection, influenza infection and / or RSV infection and induction of effective coronavirus, influenza virus and / or RSV antigen-specific immune responses, such as antibodies and / or T cell responses. Specifically, in one embodiment, the disclosure relates to a method comprising administering to a subject (i) a bivalent RNA vaccine encoding a peptide or protein comprising an epitope of SARS-CoV-2 spike protein (S protein), and (ii) a tetravalent RNA vaccine encoding a peptide or protein comprising an epitope of hemagglutinin (HA), the present invention relates to a method for inducing an immune response in a subject against a coronavirus S protein, in particular an S protein of SARS-CoV-2, and an influenza protein, in particular an HA protein of influenza A and B viruses.

The application belongs to the technical field of biological medicine, and particularly relates to a RSV pre-fusion F protein mutant and application thereof. The RSV pre-fusion F protein mutant has good stability, high expression and / or immunogenicity, and can be used for preparing a RSV antibody, preventing RSV infection, preventing and / or treating a disease caused by RSV infection, detecting the presence or content of the RSV antibody in a sample, diagnosing RSV infection, and diagnosing a disease caused by RSV infection.

The invention relates to the technical field of medical data processing, in particular to a risk assessment method and system for RSV infection. A risk assessment method for RSV infection comprises the following steps: S1, constructing a PM2.5 land utilization regression model, and obtaining the real-time concentration of PM2.5 in a target area by using the PM2.5 land utilization regression model; s2, obtaining related influence data, and obtaining the correlation between the PM2.5 exposure and the related influence data of the children with respiratory diseases caused by RSV infection according to the related influence data; and S3, according to the correlation, determining the mediation effect of the immune function change in the respiratory diseases caused by the PM2.5 exposure to the RSV infection. By prospectively researching the correlation between PM2.5 exposure and related influence data of children with respiratory diseases caused by RSV infection, the reliability and scientificity are improved.

The invention relates to an application of a PROTAC compound targeting M2-1 protein in preparation of an anti-RSV (Respiratory Syndrome Virus) drug, and belongs to the technical field of biological medicines. According to the invention, by constructing bifunctional micromolecules capable of simultaneously combining the M2-1 protein and CRBN E3 ubiquitin ligase, selective degradation of the M2-1 protein is realized, the limitation that the protein cannot be effectively targeted in the prior art is broken through, and a new technical approach is provided for solving the problems of single target spot, high drug resistance risk, lack of specific drugs and the like in RSV infection treatment; the method has obvious novelty and substantial progress.

A phospholipid-rich milk fraction for use in the prevention of viral infection of respiratory syncytial virus (RSV) and / or in the further development of the prevention of viral infection of respiratory syncytial virus (RSV) is disclosed.

Provided are an antigen-binding protein neutralizing respiratory syncytial virus (RSV) and a use thereof. The antigen-binding protein comprises a single-domain antibody containing CDR1, CDR2, and CDR3 antigen complementarity-determining regions, and has the function of exerting virus-neutralizing activity by recognizing and binding to RSV surface proteins. The antigen-binding protein can prevent or treat diseases caused by RSV infection.

The present disclosure relates to compositions comprising RNA molecules encoding an antigen derived from influenza, wherein the RNA may be formulated in a lipid nanoparticle (LNP), and wherein the composition further includes a polypeptide antigen derived from respiratory syncytial virus (RSV) and / or RNA molecules encoding an antigen derived from RSV, wherein the RSV RNA may be formulated in an LNP. The present disclosure further relates to the use of the RNA molecules, RNA-LNPs and compositions for the prevention of influenza and RSV infection-induced illness.

The present invention provides an immunogenic composition comprising recombinant peptides and proteins, the recombinant peptides and proteins comprising respiratory syncytial virus (RSV) viral antigens and immunogens, such as RSV F protein peptides. The immunogenic composition comprises a secreted fusion protein comprising a soluble RSV viral antigen, which is linked to the collagen C-terminal portion by in-frame fusion to form a disulfide-linked trimeric fusion protein. The immunogenic composition can be used to generate an immune response, such as for treating or preventing RSV infection. The immunogenic composition can be used in vaccine compositions, such as as part of a preventive and / or therapeutic vaccine. Also provided herein are methods for producing the recombinant peptides and proteins, prevention, treatment and / or diagnostic methods, and related kits.

The invention relates to the fields of immunology and molecular virology, in particular to the fields of prevention and treatment of RSV (Respiratory Syndrome Virus). Specifically, the invention provides a monoclonal antibody capable of specifically binding to a neoepitope on pre-F protein, and application of the monoclonal antibody to detection, prevention and / or treatment of RSV infection and / or diseases caused by the infection.

The invention provides an application and a method of an RSAD2 agonist glycopyrronium in resisting RSV infection. The method comprises the following steps: S1, virtual screening and molecular docking; s1.1, performing virtual screening and molecular docking; s1.2, carrying out molecular dynamics simulation; s2, cell culture and RSV infection; s3, performing RT-qPCR detection on the expression of the RSAD2 and the virus load of the RSV; s4, performing Westernblot analysis on the influence of a small molecule compound on the expression of the RSAD2; s5, CCK8 is used for detecting the toxicity of the compound to Beaas-2b cells; s6, carrying out indirect immunofluorescence detection on a fluorescence signal of the RSV; s7, animal model establishment; s8, carrying out HE dyeing; s9, carrying out enzyme-linked immunosorbent assay (ELISA); and S10, statistical analysis. According to the present invention, the small molecule agonist targeting the host immune factor RSAD2 is screened, the endogenous antiviral factor is activated from the host perspective, the drug resistance problem caused by direct virus targeting is avoided, the RSAD2 is adopted as the host natural antiviral molecule, the activation strategy has good targeting property and good safety, and the efficient anti-RSV effect under the low toxic-side effect is achieved.

The present invention relates to vaccination against respiratory syncytial virus (RSV), in particular to the use of a vaccine formulation comprising an RSV F fusion protein (RSV F protein) antigen and an adjuvant in methods of prevention of RSV infection and disease in older adults.

This invention relates to the application of methyltransferase inhibitors as adjuvants for respiratory syncytial virus (RSV) vaccines and allergy vaccines. Methyltransferase inhibitors, as adjuvants for RSV vaccines or allergy vaccines, can target and regulate the antigen presentation function of vaccine-induced memory dendritic cells (DCs), thereby regulating the balance of T cell responses and balancing the dominant Th2 and / or Th17 cellular immune responses induced by RSV vaccines or allergy vaccines. This allows the vaccine recipient to develop a balanced immune memory, providing protection while preventing the occurrence of vaccine-enhanced inflammatory diseases when RSV infection or allergen stimulation occurs, thus being both safe and effective.

The application of OsFabF gene in resistance to rice stripe virus, the application relates to the technical field of rice disease resistance breeding. The application uses a CRISPR / Cas9 gene editing system to design sgRNA targeting a specific functional region of an endogenous OsFabF gene in rice, to precisely edit the region, thereby obtaining a mutant with a functionally deficient OsFabF. The editing preferably results in a frame shift mutation or a premature stop codon, to obtain a truncated OsFabF protein mutant. Experiments show that the rice mutant plant obtained in this way exhibits significantly enhanced resistance to RSV infection, reduced virus accumulation and reduced disease symptoms. The application provides an effective gene target and breeding material for cultivating new rice varieties resistant to rice stripe virus.

Provided are a fusion protein, and a nucleic acid molecule comprising a nucleotide sequence encoding the fusion protein. The present invention also relates to a vaccine comprising the fusion protein or the nucleic acid molecule. Furthermore, the present invention also relates to a method for preventing and / or treating RSV infections or diseases and / or symptoms caused by RSV infections by means of using the fusion protein, nucleic acid molecule and vaccine.

Embodiments of a recombinant Respiratory Syncytial Virus (RSV) F ectodomain trimer stabilized in a prefusion conformation are provided. Also disclosed are nucleic acids encoding the RSV F ectodomain trimer and methods of producing the RSV F ectodomain trimer. Methods for inducing an immune response in a subject are also disclosed. In some embodiments, the method can be a method for treating or preventing a RSV infection in a subject by administering a therapeutically effective amount of the recombinant RSV F ectodomain trimer to the subject.

An immunogenic composition comprising recombinant peptides and proteins comprising respiratory syncytial virus (RSV) viral antigens and immunogens, such as RSVF protein peptides. The immunogenic composition comprises a secreted fusion protein, the secreted fusion protein comprises a soluble RSV virus antigen, and the soluble RSV virus antigen and a collagen C-terminal part are linked through in-frame fusion to form a disulfide bond linked trimeric fusion protein. The immunogenic compositions may be used to generate an immune response, for example, in the treatment or prevention of RSV infection. The immunogenic compositions may be used in vaccine compositions, for example as part of prophylactic and / or therapeutic vaccines. Also provided are methods of producing the recombinant peptides and proteins, prophylactic, therapeutic and / or diagnostic methods, and related kits.

The application belongs to the technical field of biological medicine, and particularly relates to a RSV pre-fusion F protein mutant and application thereof. The RSV pre-fusion F protein mutant has good stability, high expression and / or immunogenicity, and can be used for preparing a RSV antibody, preventing RSV infection, preventing and / or treating a disease caused by RSV infection, detecting the presence or content of the RSV antibody in a sample, diagnosing RSV infection, and diagnosing a disease caused by RSV infection.

Provided is a recombinant respiratory syncytial virus (RSV) fusion (RSV F) protein, comprising F2 and F1 polypeptides, wherein the recombinant RSV F protein contains cysteines (C) at positions corresponding to the amino acid positions 72 and 76 of SEQ ID NO: 1, and independently contains, relative to SEQ ID NO: 1, amino acid replacements at one or more positions selected from positions corresponding to the amino acid positions 67, 68, 80, 84, 87, 102, 161, 198, 202, 207, 210, 211, 213, 214, 217, 219, 379, 447, 459, 460, 463, 470, 472, 479, 481, 485, 489 and 492 of SEQ ID NO: 1. Further provided are an immunogenic composition comprising said protein, and the use thereof in the prevention and / or treatment of RSV infections.

To provide compositions for treating and / or preventing RSV infection-induced acute respiratory tract illness including pneumonia and bronchitis.SOLUTION: The disclosure provides a composition for inducing immune response to RSV, the composition comprising an RNA molecule comprising at least one open reading frame encoding a respiratory syncytial virus (RSV) fusion protein F (F) polypeptide. The disclosure further relates to a composition comprising the RNA molecule formulated in a lipid nanoparticle (RNA-LNP). The disclosure further relates to the use of the RNA molecule, RNA-LNP, and composition for treating and / or preventing RSV infection-induced acute respiratory tract illness including pneumonia and bronchitis.SELECTED DRAWING: None

The invention discloses an application of FAM20C protein or a coding gene thereof in preparation of an anti-RSV drug, and relates to the technical field of gene functions and application, and the FAM20C protein or the coding gene thereof is an action target of the drug; 1, and the amino acid sequence of the FAM20C protein is as shown in SEQ ID NO. 2. According to the invention, the relationship between the FAM20C gene / protein and RSV infection is determined, the FAM20C gene / protein can be used as a therapeutic target of RSV infection, the replication of RSV virus can be inhibited by knocking down the FAM20C gene, and the inhibitor FL-1607 of the FAM20C gene can be used for treating RSV infection. The invention provides an effective new way for the treatment of RSV (Respiratory Syndrome Virus) infection.

Provided are a recombinant respiratory syncytial virus (RSV) fusion (F) protein, and a fusion protein, vaccine, immunogenic composition, kit and pharmaceutical composition comprising same. Further provided is a use of the recombinant RSV F protein, fusion protein, vaccine, immunogenic composition, kit and pharmaceutical composition in preventing and / or treating RSV infection or diseases and / or symptoms caused by RSV infection.

In order to further reduce the risk of respiratory syncytial virus in immunocompromised populations, novel mRNA vaccines for the prevention of RSV are provided that are superior in stability and significantly enhance humoral immunity after vaccination.SOLUTION: A respiratory syncytial virus (RSV) vaccine comprising RNA encoding an RSVF protein or mutant thereof, and methods of making the same. The vaccine can prevent RSV infection and its complications.SELECTED DRAWING: Figure 1

The present disclosure relates to compositions comprising RNA molecules encoding an antigen derived from influenza, wherein the RNA may be formulated in a lipid nanoparticle (LNP), and wherein the composition further includes a polypeptide antigen derived from respiratory syncytial virus (RSV) and / or RNA molecules encoding an antigen derived from RSV, wherein the RSV RNA may be formulated in an LNP. The present disclosure further relates to the use of the RNA molecules, RNA-LNPs and compositions for the prevention of influenza and RSV infection-induced illness.

The invention relates to a nano antibody for detecting respiratory syncytial virus and application thereof. In particular to a nano antibody specifically combined with respiratory syncytial virus F glycoprotein, which comprises a CDR1 shown as SEQ ID NO: 3, a CDR2 shown as SEQ ID NO: 4 and a CDR3 shown as SEQ ID NO: 5. The nano antibody provided by the invention has the characteristics of strong specificity, high sensitivity and high stability, and has wide application prospects and important economic and social meanings in the research aspects of development of RSV infection detection reagents, targeted drug delivery, neutralizing antibody treatment and the like.

Disclosed are Respiratory Syncytial Virus (RSV) antigens including a recombinant RSV F protein stabilized in a prefusion conformation. Also disclosed are nucleic acids encoding the antigens and methods of producing the antigens. Methods for generating an immune response in a subject are also disclosed. In some embodiments, the method is a method for treating or preventing a RSV infection in a subject by administering a therapeutically effective amount of the antigen to the subject.